Clinical Relevance of Urokinase-Type Plasminogen Activator, Its Receptor, and Its Inhibitor Type 1 in Endometrial Cancer

By Tecimer C.   Doering D.L.   Goldsmith L.J.   Meyer J.S.   Abdulhay G.   Wittliff J.L.  

Gynecologic Oncology, Vol. 80, Iss. 1, 2001-01 ,pp. : 48-55

Elsevier

Access to resources Recommend Favorite

Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance

By          

Oncology Reports, Vol. 29, Iss. 2, 2013-01 ,pp. : 637-645

Spandidos Publications

Access to resources Recommend Favorite

Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients

By Strojan P.   Budihna M.   S   mid L.   Vrhovec I.   S   krk J.  

European Journal of Cancer, Vol. 34, Iss. 8, 1998-07 ,pp. : 1193-1197

Elsevier

Access to resources Recommend Favorite

Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer

By Offersen Birgitte Vrou   Riisbro Rikke   Knoop Ann   Brünner Nils   Overgaard Jens   Group on behalf of the Danish Breast Cancer Cooperative   Committee Tumor Biology  

Acta Oncologica, Vol. 46, Iss. 6, 2007-01 ,pp. : 782-791

Informa Healthcare

Access to resources Recommend Favorite

Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients

By Chung Hyun   Rha Sun   Park Joon   Yoo Nae   Kim Joo   Roh Jae   Min Jin   Lee Kyong   Kim Byung   Kim Jin  

Breast Cancer Research and Treatment, Vol. 49, Iss. 1, 1998-05 ,pp. : 41-50

Springer Publishing Company

Access to resources Recommend Favorite